Elanco Animal Health Incorporated
ELAN
Rang in aandelen
#1871
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Aandeelprijs
$22.70
Marktkapitalisatie
$11.34B
Verandering (1 dag)
-3.45%
Verandering (1 jaar)
4.49%
Land
US
Handel Elanco Animal Health Incorporated (ELAN)
Categorie
Healthcare
Winst voor Elanco Animal Health Incorporated (ELAN)
Winst in Jun 2026 TTM: $-166.00M
Volgens de meest recente financiële verslagen van Elanco Animal Health Incorporated bedraagt de huidige winst van het bedrijf $-166.00M. In 2023 behaalde het bedrijf een winst van $-1.20B, een daling ten opzichte van de winst van 2022, die $-72.00M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Elanco Animal Health Incorporated van 2015 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-166.00M | -134.02% |
| 2024 | $488.00M | -140.84% |
| 2023 | $-1.20B | 1,559.72% |
| 2022 | $-72.00M | -87.39% |
| 2021 | $-571.00M | -15.03% |
| 2020 | $-672.00M | -959.34% |
| 2019 | $78.20M | -31.46% |
| 2018 | $114.10M | -149.05% |
| 2017 | $-232.60M | 938.39% |
| 2016 | $-22.40M | -91.37% |
| 2015 | $-259.50M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -1,162.98% |
IN
|
